万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 英文名:
OS-RC-2
- 库存:
1x10^6/瓶/支
- 供应商:
上海酶研
- 肿瘤类型:
详询
- 细胞类型:
人肾细胞癌细胞
- ATCC Number:
详询
- 品系:
OS-RC-2
- 组织来源:
人肾细胞癌细胞
- 相关疾病:
OS-RC-2
- 物种来源:
哺乳动物
- 免疫类型:
详询
- 细胞形态:
贴壁/悬浮
- 是否是肿瘤细胞:
详询
- 器官来源:
人肾细胞癌细胞
- 运输方式:
顺丰快递
- 年限:
5年
- 生长状态:
生长良好
OS-RC-2/OS-RC-2细胞系/OS-RC-2细胞株/OS-RC-2人肾细胞癌细胞
Cell line name OS-RC-2
Synonyms OSRC2; RC-2
Accession CVCL_1626
Resource Identification Initiative To cite this cell line use: OS-RC-2 (RRID:CVCL_1626)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Japanese.
Doubling time: ~60 hours (Note=At 30th passage) (PubMed=4008433).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
Sequence variations
Mutation; HGNC; 9588; PTEN; Simple; p.Cys211Serfs (c.631_634+12del16); Zygosity=Heterozygous (Cosmic-CLP=909250; DepMap=ACH-000159).
Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP=909250; DepMap=ACH-000159).
HLA typing Source: PubMed=26589293
Class I
HLA-A A*24:02,24:02
HLA-B B*52:01,52:01
HLA-C C*12:02,12:02
Genome ancestry Source: PubMed=30894373
Origin % genome
African 0.1
Native American 0
East Asian, North 77.03
East Asian, South 20.25
South Asian 0
European, North 0.95
European, South 1.66
Disease Clear cell renal cell carcinoma (NCIt: C4033)
Clear cell renal carcinoma (ORDO: Orphanet_319276)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling 52Y
Category Cancer cell line
STR profile Source(s): CCRID; Cosmic-CLP=909250; RCB=RCB0735
Markers:
Amelogenin X,Y
CSF1PO 12,13
D2S1338 20
D3S1358 17
D5S818 11,12
D7S820 10,11
D8S1179 14
D13S317 8,12
D16S539 11
D18S51 14
D19S433 13,14
D21S11 31.2
FGA 24
TH01 6
TPOX 8,11
vWA 16
Run an STR similarity search on this cell line
Publications
PubMed=4008433; DOI=10.1007/BF02620929
Kinouchi T., Kotake T., Mori Y., Abe T.
Human renal cell carcinoma: establishment and characterization of a new cell line (OS-RC-2).
In Vitro Cell. Dev. Biol. 21:195-199(1985)
PubMed=14534724; DOI=10.3892/or.10.6.1947
Ikemoto S., Narita K., Yoshida N., Wada S., Kishimoto T., Sugimura K., Nakatani T.
Effects of tumor necrosis factor alpha in renal cell carcinoma.
Oncol. Rep. 10:1947-1955(2003)
PubMed=15604581; DOI=10.1159/000081597
Ikemoto S., Sugimura K., Yoshida N., Kuratsukuri K., Wada S., Nakatani T.
Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with interferon-alpha in renal cell carcinoma cell lines.
Urol. Int. 73:348-353(2004)
PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)
PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., M, Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)
PubMed=28489074; DOI=10.1038/ncomms15165; PMCID=PMC5436135
Sinha R., Winer A.G., Chevinsky M.S., Jakubowski C., Chen Y.-B., Dong Y.-Y., Tickoo S.K., Reuter V.E., Russo P., Coleman J.A., Sander C., Hsieh J.J.-D., Hakimi A.A.
Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection.
Nat. Commun. 8:15165.1-15165.10(2017)
PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验*发表【中文论文】请标注:由上海酶研生物科技有限公司提供;
*发表【英文论文】请标注:From Shanghai EK-Bioscience Biotechnology Co., Ltd.
a look from the following website just by clicking "Tyrosine Phosphorylation and Dimerization" http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WSN-43F85YV-2&_user=1111158&_coverDate=06%2F29%2F2001&_rdoc=1&_fmt=full&_orig=search
扫描仪中,都采用机械式的二维X,Y线性扫描技术实现,即X,Y方向都采用直线驱动器和直线导轨实现往复运动。此类装置,由于驱动系统的频率限制,驱动器的扫描惯性大,使得扫描效率低,分析时间相当长;并且往复行程长,对直线导轨的精度要求相当高。二、光机结合的二维扫描系统为同样实现生物芯片的二维扫描,我们的实验装置设计如图2,采用了振镜和大数值孔径的远心f-è物镜相结合实现X方向扫描,Y方向的运动仍采用直线驱动器和直线导轨实现。 系统中,对于f-è物镜,满足x=2fè(è为振镜的摆动角度,f为物镜焦距)的线性
Analysis of RB Action in DNA Damage Checkpoint Response
checkpoint response: (1) transcriptional repression of E2F-regulated genes (cyclin A reporter assay); (2) induction of cell cycle arrest (Brd-U incorporation assay); and (3) inhibition of DNA double-strand break accumulation (phosphorylated-histone H2A.X
技术资料






